Drug intelligence / Profile preview

CX12

Development stage: Preclinical
Lead developer: Hangzhou Bangshun Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

CX12 is a preclinical-stage small molecule inhibitor targeting Methyltransferase-like 3 (METTL3), developed by Hangzhou Bangshun Pharmaceutical (Biosun Pharma). METTL3 is the catalytic subunit of the N6-methyladenosine (m6A) methyltransferase complex, which plays a critical role in RNA epigenetics by regulating mRNA stability, splicing, and translation. Dysregulation of m6A methylation is implicated in the progression and immune evasion of various cancers. CX12 is being developed for the treatment of solid tumors, both as a monotherapy and in combination with other agents. The sponsor expects to submit an Investigational New Drug (IND) application for CX12 in 2027.

Targets

METTL3 (Methyltransferase-like protein 3)

Beyond the preview

Go deeper on CX12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CX12.

Explore the full profile